New Coverage-With-Evidence-Development Guidance In The Works Following MedCAC Meeting
This article was originally published in The Gray Sheet
Executive Summary
The Medicare Evidence Development & Coverage Advisory Committee was charged May 16 with helping CMS better define the evidence threshold under which the agency should or should not pursue a coverage- with-evidence-development policy.
You may also be interested in...
Device Makers Seek Clarity On CMS' Plans For Coverage With Evidence Development
Many stakeholders want CMS to restrict conditional coverage to national determinations and prevent local Medicare carriers from imposing their own CED policies.
Washington Roundup, January 2013
The latest medical device regulatory and reimbursement news from Elsevier Business Intelligence’s “The Gray Sheet.” This month we cover FDA’s proposal to require PMAs for metal-on-metal hips, the launch of the Medical Device Innovation Consortium, CMS draft guidance on CED, and a recent analysis of the potential impact of the Affordable Care Act on device markets.
Washington Roundup, November-December 2012
The latest medical device regulatory and reimbursement news from Elsevier Business Intelligence’s “The Gray Sheet.” This month we cover the post-election picture, pending reimbursement reductions for interventional cardiologists, and new guidance on PMA and 510(k) submission reviews.